The Substances on the Table These are the drugs being reviewed and the medical uses FDA will be evaluating: July 23, 2026: BPC-157 (free base and acetate) ulcerative colitis KPV (free base and acetate) wound healing and inflammatory conditions TB-500 (free base and acetate) wound healing MOTs-C (free base and acetate) obesity and osteoporosis July 24, 2026: Emideltide / DSIP (delta sleep-inducing peptide, free base and acetate) opioid withdrawal, chronic insomnia, and narcolepsy Semax (free base and acetate) cerebral ischemia, migraine, and trigeminal neuralgia Epitalon (free base and acetate) insomnia If any or all of these substances are added to the 503A Bulks List following this process, it would formalize the legal pathway for licensed pharmacists and physicians to compound them for patients
This process supports reliable and repeatable outcomes in research applications
Health Canada has not approved BPC-157 for medical use, meaning it cannot be legally sold as a drug or therapeutic product
Reported Side Effects (rare) Mild fatigue or dizziness Temporary headache Injection site irritation Nausea (usually mild and transient) Safety Notes Should only be sourced from pharmaceutical-grade compounding pharmacies BPC-157 is prohibited by WADA for competitive athletes How Nulevel Wellness Medspa Personalizes BPC-157 Dosage Unlike generalized online dosing charts, Nulevel Wellness Medspa in Gilbert, AZ designs personalized BPC-157 protocols under medical supervision
Patience and adherence to the prescribed injection schedule are essential for optimal outcomes
The tapeworm from undercooked fish ( Diphyllobothrium latum ) absorbs huge quantities of vitamin B 12 , and infested patients often have associated gastric atrophy